Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian High Grade Endometrioid Adenocarcinoma: full-pipeline trial registry
1 of 2 indexed Ovarian High Grade Endometrioid Adenocarcinoma trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Ovarian High Grade Endometrioid Adenocarcinoma: 2 US clinical trials tracked, 1 recruiting.
Ovarian High Grade Endometrioid Adenocarcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition ovarian-high-grade-endometrioid-adenocarcinoma
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Ovarian High Grade Endometrioid Adenocarcinoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian High Grade Endometrioid Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian High Grade Endometrioid Adenocarcinoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
NCT06580314
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT02345265
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian High Grade Endometrioid Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian High Grade Endometrioid Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian High Grade Endometrioid Adenocarcinoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Ovarian High Grade Endometrioid Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NRG Oncology sponsors the most Ovarian High Grade Endometrioid Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian High Grade Endometrioid Adenocarcinoma condition card totals 2 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.